openPR Logo
Press release

Novalung now in “Future Park”

11-10-2010 04:01 PM CET | Health & Medicine

Press release from: Novalung

Novalung CEO Dr Matheis and COO Wetscher inaugurated the new headquarters

Novalung CEO Dr Matheis and COO Wetscher inaugurated the new headquarters

The innovative medical device company moves into new headquarters in Southern Germany

On October 27th the new head office of Novalung GmbH was officially opened. During a short celebration CEO Dr. Georg Matheis and COO Hannes Wetscher inaugurated the new offices located in the newly constructed technology park “Zukunftspark” (Future Park) in Heilbronn, approximately halfway between Stuttgart and Frankfurt in the South of Germany.

”Our innovative solutions for lung failure are gaining wide acceptance. We have numerous concepts for further urgently needed product developments. In order to implement these concepts we need sufficient space. Now,finally, we have the space here that we need“, Matheis noted. ”We are glad to finally be here in Heilbronn. The move into the ”Zukunftspark“ means being a step closer towards consolidation of our headquarters and manufacturing site. We also expect to benefit from the technical competencies of the other companies here“, says Wetscher.

Novalung is one of the first tenants in the Heilbronn “Zukunftspark”. After the groundbreaking ceremony in September last year the new premises were completed on time for the scheduled move in mid October. The ”Future Park“ was initiated by the Zukunfstfonds Heilbronn, Novalung’s lead investor. The new technology park was built by the city of Heilbronn for research and development oriented companies.

The relocation is a sign of Novalung‘s constant growth. After the founding of the company and initial operations in Germany’s ”Medical Valley“ in the city of Hechingen, its headquarters moved two years ago into temporary offices outside of Heilbronn. Novalung’s manufacturing operations also moved into a new, larger clean-room facility in the Heilbronn area at the end of 2009.

Novalung - history
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further. The goal is to replace the damaging invasive ventilation. The overall objective is to replace damaging invasive mechanical ventilation.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and a subsidiary on the campus of the University of Michigan at Ann Arbor, USA.

Novalung – Driver of a paradigm shift
Novalung products allow a paradigm shift from the mechanically ventilated patient in an artificial coma to the awake, mobile patient breathing spontaneously. The innovative technologies to replace mechanical ventilation and eliminate the associated ventilator-induced lung injury continue this approach and provide physicians, nurses and patients with new therapeutic options.

Novalung‘s vision for the future for the long-term treatment of patients with advanced lung disease is a small, wearable artificial lung that frees patients from respiratory stress, improves their overall condition and thus improves their quality of life.

You can download high-resolution pictures as well as the literature compendium on www.novalung.com or it will be sent on request via email.

Please send us a copy of your imprint.

Contact:

Mrs Franziska Preissing
Head of Marketing
franziska.preissing@novalung.com
Phone: +49 7131 27 06 130
Fax: +49 7131 27 06 230

Novalung GmbH
Im Zukunftspark 1
Germany, 74076 Heilbronn
www.novalung.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novalung now in “Future Park” here

News-ID: 151127 • Views: 1073

More Releases for Heilbronn

PANATecs GmbH in new facilities in Heilbronn
2013/02/13 PANATecs is moving into modern, custom-built facilities in Heilbronn PANATecs GmbH relocated its headquarters late last year from Tübingen to Heilbronn, where housing firm Stadtsiedlung Heilbronn constructed modern laboratory facilities at the Wohlgelegen research park in accordance with PANATecs’ specifications and GMP standards. At the time of the move, PANATecs also expanded its portfolio to include CEF pools for immunological purposes - available up to now among others - and the P-CHECK®
New customer for WOLFFKRAN in Frankfurt - FABER & SCHNEPP buys its first WOLFF
Frankfurt – August 2011. The municipal fire department of Frankfurt is expanding its facilities with a new training center situated adjacent to the current training and administration building. The construction work is scheduled to be completed by fall 2012. In order to realize this project, the mid-sized construction company FABER & SCHNEPP Hoch- und Tiefbau GmbH & Co. KG in Gießen, which received the contract for carrying
Novalung and Medos start cooperation
Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies. The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this
Novalung records 50% growth
The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance. Additional financing will allow the Talheim (Germany) based company to accelerate the development of new products. Novalung GmbH increased sales by 50% in 2009. The positive trend continues through the first months of 2010. The increasing acceptance of the company’s innovative therapies for lung failure both in Germany and abroad is driving continuing growth. Manufacturing
greenovation increases investment in GMP-compliant process development for produ …
The primary objective of the investment is the implementation of a stable production platform for the manufacture of glycoproteins for industrial pharmaceutical applications, in accordance with GMP (Good Manufacturing Practice) guidelines - Gregor Mirow succeeds Hans Bodo Hartmann as the new managing director of greenovation Biotech GmbH Heilbronn, Germany – August 28th, 2008 – greenovation Biotech GmbH is investing in an accelerated implementation of its technical production platform in order
greenovation launches Bryo-Speed™ and Bryo-Master™ for the production of the …
From pilot study to stable production: in Bryo-Speed™ and Bryo-Master™ greenovation presents a production platform for custom-made pharmaceuticals – Presentation of the new products at BioProduction 2007 in Berlin Heilbronn/ Germany – November 1st 2007 – greenovation.com. Bryo-Speed™ and Bryo-Master™ are greenovation’s innovative production systems for the effective optimization and creation of pharmaceutically highly efficient glycoproteins: The production platform is based on bryotechnology which has been developed by greenovation